Skip to content

Viridian Therapeutics, Inc. VRDN Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
PVL
Palvella TherapeuticsPVLA
TG Therapeutics logo
TG TherapeuticsTGTX
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%
Enterprise value$1.77B+85.0%
P/S26.9×-3,445×

Profitability

See full
Gross margin36.3%
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s operating lease right-of-use assets in other assets?
Viridian Therapeutics, Inc. (VRDN) reported operating lease right-of-use assets in other assets of $2.26M in Q1 2026.
How has Viridian Therapeutics, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
Viridian Therapeutics, Inc.'s operating lease right-of-use assets in other assets increased by 7.8% year-over-year, from $2.09M to $2.26M.
What is the long-term trend for Viridian Therapeutics, Inc.'s operating lease right-of-use assets in other assets?
Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s operating lease right-of-use assets in other assets has grown at a 89.1% compound annual growth rate (CAGR), from $100K to $2.42M.